



Universiteit
Leiden
The Netherlands

Genetic variants contribute to differences in response and toxicity to drugs used in autoimmune diseases: Rheumatoid arthritis and systemic lupus erythematosus

Dávila Fajardo, C.L.

Citation

Dávila Fajardo, C. L. (2020, September 29). *Genetic variants contribute to differences in response and toxicity to drugs used in autoimmune diseases: Rheumatoid arthritis and systemic lupus erythematosus*. Retrieved from <https://hdl.handle.net/1887/136914>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/136914>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/136914> holds various files of this Leiden University dissertation.

Author: Dávila Fajardo, C.L.

Title: Genetic variants contribute to differences in response and toxicity to drugs used in autoimmune diseases: Rheumatoid arthritis and systemic lupus erythematosus

Issue date: 2020-09-29

**Genetic variants contribute to differences in response and
toxicity to drugs used in autoimmune diseases:
Rheumatoid arthritis and Systemic lupus erythematosus**

Cristina Lucía Dávila Fajardo

The research presented in this thesis was performed at the department of Pharmacy of Hospital Universitario San Cecilio, Granada, Spain, and the department of Clinical Pharmacy and Toxicology of Leiden University Medical Center, Leiden, The Netherlands. Financial support for publication of this thesis was provided by departmental funds from the department of Clinical Pharmacy & Toxicology of the Leiden University Medical Center, Leiden, the Netherlands.

Cover Cristina Lucía Dávila Fajardo

Cover image Shutterstock, 1409838749

Layout Renate Siebes | Proefschrift.nu

Printed by Ridderprint, Alblasserdam

ISBN 978-94-92026-16-3

© Cristina Lucía Dávila Fajardo 2020

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage or retrieval, without permission in writing from the author.

**Genetic variants contribute to differences in response and
toxicity to drugs used in autoimmune diseases:
Rheumatoid arthritis and Systemic lupus erythematosus**

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op dinsdag 29 september 2020
klokke 10.00 uur

door

Cristina Lucía Dávila Fajardo

geboren te Granada, Spanje
in 1977

Promotor Prof. dr. H.-J. Guchelaar

Copromotor Dr. J.J. Swen

Leden promotiecommissie Prof. dr. A.H.M. van der Helm-van Mil

Prof. dr. J. Burggraaf

Prof. dr. B. Wilffert, Rijksuniversiteit Groningen

Prof. dr. B.W.F. van den Bemt, Radboud UMC

Contents

Chapter 1	General introduction and outline of the thesis	7
Chapter 2	Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate	17
Chapter 3	Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis	39
Chapter 4	Confirmation of -174G/C <i>interleukin-6</i> gene promoter polymorphism as a genetic marker predicting anti-TNF treatment outcome	57
Chapter 5	<i>FcGR</i> genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis	71
Chapter 6	Association between -174 <i>Interleukin-6</i> gene polymorphism and biological response to rituximab in several systemic autoimmune diseases	91
Chapter 7	Association of the <i>FCGR3A-158F/V</i> gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients	103
Chapter 8	<i>IL2/IL21</i> region polymorphism influences response to rituximab in systemic lupus erythematosus patients	117
Chapter 9	Summary	131
Chapter 10	Samenvatting	137
Chapter 11	General discussion and future perspectives	143
Appendix	List of publications	162
	Curriculum vitae	163
	Acknowledgements	164